Back to search results

Observational Study of Zuranolone for Postpartum Depression

This study is looking at how symptoms of postpartum depression (PPD) change in people who start taking zuranolone. Zuranolone is a medication prescribed for PPD, which can cause feelings of sadness, tiredness, and a lack of interest in daily activities after childbirth. This is an "observational" study, meaning researchers will collect health information without changing your medical care. You might be able to join if you are a woman aged 18 or older, have a new prescription for zuranolone from Accredo Specialty Pharmacy, had a baby in the last 12 months, and have a confirmed diagnosis of PPD. The main goal is to see how much your PPD symptoms improve by Day 15, as measured by a questionnaire called the Edinburgh Postnatal Depression Scale (EPDS). The study is currently unclear on its recruitment status and plans to enroll 200 participants.

Study design
This is an observational study, meaning it collects health information without changing your medical care. It plans to enroll 200 women.
What's involved
You would complete questionnaires in English, including the Edinburgh Postnatal Depression Scale (EPDS) at Day 0, Day 15, Day 45, and Day 90. You would also answer questions about breastfeeding and treatment usage.
Compensation
Not stated in the trial record.
Follow-up
Your symptoms will be assessed at Day 15, Day 45, and Day 90 after starting zuranolone.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07398469

A Long-Term Study of Patient-Reported Changes in Postpartum Depression Symptoms in People Starting Zuranolone

Recruiting
Not specifiedAges 18+Observational
Biogen
~200 participants
Updated 2026-02-10 on ClinicalTrials.gov
What's tested:Zuranolone

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change From Baseline in the Edinburgh Postnatal Depression Scale (EPDS) Score at Day 15
Measured over Baseline (Day 0), Day 15

Conditions

Postpartum Depression

Explore related trials

Postpartum Depression

Where it's being run

1 sites across 1 states
Massachusetts1

Study leadership

  • Medical Director · STUDY_DIRECTOR · Biogen

Who to contact

US Biogen Clinical Trial Center
[email protected]
866-633-4636
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participants with a prescription for zuranolone via Accredo Specialty Pharmacy.
Recent pregnancy in the last 12 months.
Confirmed diagnosis of PPD.
Able to complete the questionnaires by themselves in English.

Exclusion

Prior fill of zuranolone or brexanolone in last 12 months.
Participants who have taken 1 or more doses of zuranolone at the time of study screening.
Current or history of bipolar disorder.
Failure to complete baseline (Day 0) surveys.
Declined to consent.
Pregnancy that ended more than 12 months ago.

What this trial measures

  • Change From Baseline in the Edinburgh Postnatal Depression Scale (EPDS) Score at Day 15Baseline (Day 0), Day 15

    EPDS is a 10-item self-report questionnaire used for the assessment of PPD symptoms. Each item is scored from 0-3, with a total score range of 0-30. Higher scores indicate more severe depressive symptoms.